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Abstract
Hepatocellular carcinoma (HCC) is a common malignant tumor that severely threatens human health. The poor
prognosis of HCC is mainly attributed to intrahepatic and extrahepatic metastases. HOXD9 proteins belong to a
superfamily that regulates the development and control of many cellular processes, including proliferation,
apoptosis, cell shape, and cell migration. HOXD9 can also function as an oncogene in several cancer cells. However,
its biological function in human HCC requires further investigation. In this study, HOXD9 exhibited high expression
in invasive HCC cells. HOXD9 overexpression can significantly enhance HCC cell migration, invasion, and metastasis,
whereas silencing HOXD9 inhibits these processes. HOXD9 also promotes the epithelial–mesenchymal transition
(EMT) of HCC cells. Microarray analysis suggests that ZEB1 can function as a downstream factor of HOXD9. HOXD9
can interact with the promoter region of ZEB1 and promotes ZEB1 expression. ZEB1 knockdown inhibits HOXD9-
induced migration and invasion, as well as EMT in HCC cells. This study helps elucidates the oncogenic functions of
HOXD9 in HCC.
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Background
Hepatocellular carcinoma (HCC) is the sixth most
prevalent cancer and the third leading cause of cancer-
related mortality worldwide [1]. The poor prognosis of
this disease is attributed to tumor metastasis, frequent
intrahepatic spread, and extrahepatic metastasis during
the initial diagnosis [1].
Homeobox (HOX) genes encode a highly conserved
family of transcription factors that significantly influence
many cellular processes, including proliferation, apop-
tosis, cell shape, and cell migration. HOX genes contain
a conserved 183 bp sequence and encode nuclear pro-
teins called homeoproteins. HOX proteins provide an
axial pattern during embryonic development [2–4], and
HOX genes can also control normal cellular prolifera-
tion and differentiation in different tissues [5–7]. In
neoplasms and cancer cells, HOX proteins participate in
proliferation and oncogenic transformation [7]. HOX
gene expression has been altered in many cancer tissues,
such as liver carcinoma, neuroblastoma, ovarian carcin-
oma, cervical carcinoma, prostate carcinoma, breast car-
cinoma, and leukemia [8]. The HOX family has four
HOX gene clusters: HOXA, HOXB, HOXC, and HOXD.
These clusters are located on different chromosomes in
tandem. HOXD9 is one of the HOXD genes located
closest to the 3′ end of the chromosome. This gene par-
ticipates in the development and patterning of the fore-
limb and axial skeleton [8]. Studies have demonstrated
the relation of HOXD9 to epigenetic control in develop-
ment and diseases [9]. The DNA methylation of the
HOXD9 gene promoter affects transcript and protein
expression and is significantly higher in melanoma brain
metastasis than that in the early stages [10]. HOXD9 is
important for embryonic segmentation and limb bud
patterning during development; however, the biological
function in human HCC remains poorly understood.
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Epithelial–mesenchymal transition (EMT) refers to
specific morphological and phenotypic alterations in epi-
thelial cells during embryonic development [11]. In the
EMT process, the polarity and adhesion of cells sur-
rounding the epithelial cells and matrix is reduced and
becomes similar in morphology to fibroblasts; thus, this
process enhances migratory ability [12]. The occurrence
of EMT is accompanied by different expression-specific
epithelial and mesenchymal molecular markers [13].
In EMT, epithelial cell markers such as E-cadherin, α-
catenin, β-catenin, and γ-catenin are downregulated,
whereas the expression levels of mesenchymal tissue
markers such as N-cadherin, α-smooth muscle actin,
vimentin, and fibronectin protein are upregulated
[12]. EMT is closely associated with tumor progres-
sion and resistance to chemotherapy [14, 15]. This
finding has drawn the attention of academics, clini-
cians, and pharmaceutical researchers to EMT.
Primary liver cancer is a common malignant tumor
and severely threatens human health. The poor prog-
nosis of this type of cancer is mainly attributed to
intrahepatic and extrahepatic metastases [16]. A study
has shown that EMT increases the invasive ability of
cancer cells, thus inducing distant metastasis [17, 18].
Exploring the molecular mechanism of EMT can
greatly contribute to the understanding of tumor pro-
gression and metastasis.
This study demonstrates that HOXD9 overexpression
can significantly enhance the migration, invasion, and
metastasis of HCC cells. HOXD9 also promotes the
EMT of HCC cells. Microarray analysis indicates that
HOXD9 performs its functions by regulating ZEB1.
ZEB1 knockdown inhibits HOXD9-induced migration
and invasion and the EMT of HCC cells. The results of
this study can elucidate the oncogenic functions of
HOXD9 in liver cancers.
Materials and methods
Chemicals and antibodies
Lipofectamine 2000 transfection and TRIZOL LS Re-
agents were purchased from Invitrogen (Grand Island,
NY, USA). Antibodies against HOXD9, and ZEB1 were
purchased from Abcam (Cambridge, MA, USA). E-
cadherin, Fibronectin, N-cadherin, vimentin, and β-
actin antibodies were from Cell Signaling technology
(Danvers, MA, USA). Anti-α-catenin antibody was
from BD (Franklin Lakes, NJ, USA). Unless otherwise
noted, all other chemicals were from Sigma (St. Louis,
MO, USA).
Patients and specimens
One hundred two tumor tissues which, were used for
qRT-PCR and immunohistochemical analysis, were ran-
domly collected from HCC patients who underwent
curative resection with informed consent between 2007
and 2010 at the First Affiliated Hospital of Dalian Med-
ical University. All tissues were collected immediately
upon resection of the tumors in the operation theater,
transported in liquid nitrogen, and then stored at −80 °C.
Tumor staging was based on the 6th edition of the tumor-
node-metastasis (TNM) classification of the International
Union Against Cancer. The clinicopathologic characteris-
tics of the hepatocellular carcinoma tissues are summa-
rized in Additional file 1: Table S1. Follow-up data were
summarized at the end of May 2015, with a median obser-
vation time of 65.3 months. Study protocols were ap-
proved by the First Affiliated Hospital of Dalian Medical
University, and written informed consent was obtained
from patients based on the Declaration of Helsinki.
Histological and immunohistochemical analysis
The normal human liver tissues, human tumor tissues,
and lungs dissected from mice were fixed in 4 % parafor-
maldehyde in phosphate-buffered saline (PBS) overnight
and subsequently embedded in paraffin wax. Sections cut
at a thickness of 4 μm were stained with hematoxylin
and eosin for histological analysis. Immunohistochem-
ical analysis was performed for different markers in
these arrays as described previously [19]. The proportion
of stained cells (lower, <30 % staining; higher, ≥30 % stain-
ing) was semiquantitatively determined following pub-
lished protocols [20].
Cell culture
HCC cells (ATCC, Manassas, VA, USA) were cultured
under the following conditions: L-O2 cell line was cul-
tured using 10 % fetal bovine serum (Cat#10099-141,
Invitrogen, Carlsbad, CA) in either RPMI-1640
(Cat#C11875, Invitrogen). Huh7, HepG2, and MHCC97H
cell lines were cultured using 10 % fetal bovine serum
(Invitrogen) in Dulbecco’s modified Eagle medium
(Cat#C11965, Invitrogen). Cell culture was according to
manufacturer’s protocol. All the cell lines were grown at
37 °C in a 5 % CO2/95 % air atmosphere and were revived
every 3 to 4 months.
Establishment of stable expression and knockdown cell
lines
Retroviral construct containing human pBabe-HOXD9
cDNA and pSuper.retro.puro with shRNA against hu-
man HOXD9 and siZEB1s were prepared as described
previously [20]. The generation of retrovirus superna-
tants and transfection of hepatocellular carcinoma cells
were conducted as described previously [21]. The ex-
pression of HOXD9 and ZEB1 was confirmed by qRT-
PCR and Western blotting analysis.
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Cell invasion and motility assay
Invasion of cells was measured in Matrigel (BD,
Franklin Lakes, NJ, USA) -coated Transwell inserts
(6.5 mm, Costar, Manassas, VA, USA) containing
polycarbonate filters with 8-μm pores as detailed pre-
viously [22]. The inserts were coated with 50 μl of
1 mg/ml Matrigel matrix according to the manufac-
turer’s recommendations. 2 × 105 cells in 200 μl of
serum-free medium were plated in the upper cham-
ber, whereas 600 μl of medium with 10 % fatal bovine
serum were added to lower well. After 24 h incuba-
tion, cells that migrated to the lower surface of the
membrane were fixed and stained. For each mem-
brane, five random fields were counted at × 10 magni-
fication. Motility assays were similar to Matrigel
invasion assay except that the Transwell insert was
not coated with Matrigel.
Confocal immunofluorescence microscopy
Cell lines were plated on culture slides (Costar, Manas-
sas, VA, USA). After 24 h, the cells were rinsed with PBS
and fixed with 4 % paraformaldehyde, and cell mem-
brane was permeabilized using 0.5 % Triton X-100.
These cells were then blocked for 30 min in 10 % BSA
and then incubated with primary antibodies overnight at
4 °C. After three washes in PBS, the slides were incu-
bated for 1 h in the dark with FITC-conjugated second-
ary antibodies (Invitrogen, Grand Island, NY, USA).
After three further washes, the slides were stained with
DAPI for 5 min to visualize the nuclei, and examined
using a Carl Zeiss confocal imaging system (LSM 780)
(Carl Zeiss, Jena, Germany).
Western blotting
Cells were lysed in lysis buffer and total protein contents
were determined by the Bradford method. 30 μg of lysis
were separated by reducing SDS-PAGE and probed
with specific antibodies. Blots were washed and
probed with respective secondary peroxidase-conjugated
antibodies, and the bands visualized by chemolumines-
cence (Amersham Biosciences).
qRT-PCR
Total RNA was extracted using Trizol reagent and
cDNA was synthesized using SuperScript II Reverse
Transcriptase (Invitrogen). qRT-PCR and data collection
were performed with an ABI PRISM 7900HT sequence
detection system. The primers used for the amplification
of the indicated genes are available upon request.
Fig. 1 HOXD9 expression is correlated with metastasis of human cancers. a HOXD9 expression in liver cancer cell lines determined by Western blot
analysis. b Quantitative chart of HOXD9 protein level in liver cancer cell lines. c HOXD9 expression in liver cancer cell lines analyzed by qRT-PCR.
d Semi-quantification of HOXD9 expression in cancer tissues without distant metastasis and with distant metastasis. P < 0.001 in panel D based on
Student’s t-test. Error bars, SD
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Gene expression profiling
Total RNA quality and quantity were determined using
Agilent 2100 Bioanalyzer and NanoDrop ND-1000. Affy-
metrix HU U133 plus 2.0 arrays were used according to
manufacturer’s protocol. The data were initially normal-
ized by robust multiarray average (RMA) normalization
algorithms in expression console software (Affymetrix).
Significantly altered genes between HOXD9 knockdown
and its control cells were considered by scatter plots and
the genes up- and down-regulated ≥5-fold. Clustering
analysis was done using gene list by Gene Cluster v3.0
software, and heat maps were visualized using Java Tree-
View v1.1.4r3 software. Gene set enrichment analysis
was carried out using ConceptGen. Gene sets were ei-
ther obtained from the ConceptGen or from published
gene signatures.
Chromatin immunoprecipitation (ChIP)-qPCR
Chromatin Immunoprecipitation kit (Cat. 17–371) was
purchased from Millipore and ChIP experiments were
carried out essentially as described [22]. Immnuoprecipi-
tated DNA was analyzed on the ABI PRISM 7900HT se-
quence detection system. The primers used for detection
of promoters after ChIP are available upon request.
In vivo tumor metastasis
Nude mice were purchased from the Shanghai Slac
Laboratory Animal Co. Ltd and maintained in microi-
solator cages. All animals were used in accordance
with institutional guidelines and the current experi-
ments were approved by the Use Committee for
Animal Care. For metastasis assays, cells were resus-
pended in PBS at a concentration of 1×107 cells ml−1.
Cell suspension (0.1 ml) was injected into tail veins
of nude mice. All of the mice were killed by CO2
60 days after inoculation.
Statistical analysis
Data was described as the mean ± s.d.. Association be-
tween ZEB1 and HOXD9 expression in HCC tissues was
assessed using Spearman’s rank correlation test. Compari-
sons between different groups were undertaken using the
Student’s two-tailed t-test or ANOVA test. The survival
probability was estimated by Kaplan-Meier method, and
the comparison of survival curves between groups was
done with the log-rank test. The statistical significance of
the differences between mean values was determined
by P < 0.05. Statistical analysis was done with SPSS/
Win11.0 software (SPSS, Inc., Chicago, Illinois, USA).
Fig. 2 HOXD9 was highly expressed in tumor tissues. a Representative images of HOXD9 expression in tumor and noncancerous tissues. b and
c Quantitative chart of HOXD9 expression in tumor and noncancerous tissues. d Survival analysis of patients with liver cancer. P = 0.0031 in panel
d on the basis of Kaplan-Meier survival analysis. Error bars, SD
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Results
HOXD9 is highly expressed in malignant cancers
Compared with normal liver cells, HOXD9 showed a
significantly high expression of liver cancer cells, par-
ticularly in invasive cancer cells (Fig. 1a, b, and c). In
liver cancer cells, the protein level of HOXD9 was thrice
higher than that of normal liver cells. The protein level
of HOXD9 in invasive cancer cells is approximately 1.5
times higher than in noninvasive cancer cells. The
mRNA level of HOXD9 was also determined, and the
Fig. 3 Silencing HOXD9 in liver cancer cells decrease the migration and invasion of liver cancer cells. a Western blot analysis of HOXD9 levels in the
established cell lines. b qRT-PCR analysis of HOXD9 levels in the established cell lines. c Liver cancer cells with silent expression of HOXD9 exhibit less
invasive abilities in Transwell and Matrigel assays. d Silencing HOXD9 significantly decreased the number of mice with distant metastasis. e and f Fewer
metastatic foci in the liver were observed in each mouse injected with liver cancer cell silencing HOXD9. P < 0.01 is based on Student’s t- test. Error
bars, SD
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results were consistent with those described above
(Fig. 1c). To further examine the relationship between
HOXD9 and distant metastasis, liver cancer tissues were
analyzed. HOXD9 expression was significantly correlated
with distant metastasis (Additional file 2: Figure S1 and
D). Immunohistochemistry reveals that 97 % of tumor
tissues were moderately or strongly HOXD9 positive
(Fig. 2a and b). By contrast, 92 % of noncancerous tis-
sues are HOXD9 negative (Fig. 2a and c). The survival
curves in Fig. 2d indicates that patients with higher
HOXD9 level in liver cancer tissues had shorter longev-
ity than those with lower HOXD9 expression. This find-
ing suggests a negative correlation between HOXD9 and
long survival.
Fig. 4 HOXD9 overexpression in liver cancer cells increase the migration and invasion of liver cancer cells. a Western blot analysis of HOXD9 levels in
the established cell lines. b qRT-PCR analysis of HOXD9 levels in the established cell lines. c Liver cancer cells with high HOXD9 expression exhibited
stronger invasive abilities in Transwell and Matrigel assays. d HOXD9 overexpression significantly decreased the number of mice with distant metastasis.
e and f More metastatic foci in liver were counted in each mouse injected with liver cancer cells silencing HOXD9. P < 0.01 is based on Student’s t-test.
Error bars, SD
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HOXD9 promotes migration and invasion of liver cancer
cells
The silencing and stable overexpression of HOXD9 in
liver cancer cells were retrovirally established by using
MHCC97H and Huh7 cell lines, respectively, and desig-
nated as MHCC97H-shHOXD9 #1, #2, and #3 and
Huh7-HOXD9. The levels of HOXD9 in these cell lines
were verified on protein and mRNA levels (Fig. 3a and
b; Fig. 4a and b). Transwell and Matrigel assays were
performed to evaluate the effects of HOXD9 on migra-
tion and invasion in liver cells. Silencing HOXD9 can
significantly reduce the number of cells migrating
through the membrane to the bottom of the aperture.
Statistical analysis indicated that only about half of the
cells with HOXD9 silencing migrate through the mem-
brane (Fig. 3c). By contrast, the number of cells with
high HOXD9 expression was five times higher than the
cells with an empty vector (Fig. 4c). Matrigel assay was
used to evaluate the invasive potential of liver cancer
cells with altered HOXD9 expression. The number of in-
vaded liver cancer cells was significantly reduced by
silencing HOXD9,whereas that in the cell line with high
HOXD9 expression increased (Figs. 3c and 4c). These
results indicate that HOXD9 promotes the migration
and invasion of liver cancer cells.
To detect the function of HOXD9 in distant metasta-
sis in vivo, MHCC97H-shHOXD9#3, Huh7-HOXD9,
and their corresponding control cells were injected into
nude mice by the tail vein. Silencing HOXD9 signifi-
cantly decreases the number of mice with distant metas-
tasis (Fig. 3d). Furthermore, a low number of metastasis
foci in liver (Fig. 3e and f) were counted in each mouse
injected with liver cancer cells silencing HOXD9. By
contrast, HOXD9 expression increases the number of
metastatic mice (Fig. 4d) and metastatic foci in liver
(Fig. 4e and f).
HOXD9 regulates the transition between epithelial and
mesenchymal phenotypes in liver cancer cells
The expression levels of EMT protein markers were
evaluated to determine the relationship between
HOXD9 and EMT. In the HOXD9 silencing cell lines,
Fig. 5 HOXD9 regulates the transition between epithelial and mesenchymal phenotypes in liver cancer cells. a and b Western blot analysis (a) and
qRT-PCR analysis (b) showed that silencing HOXD9 causes upregulation of the epithelial cell markers and downregulation of mesenchymal cell
markers. c and d Western blot analysis (c) and qRT-PCR analysis (d) show that HOXD9 overexpression leads to the downregulation of epithelial cell
markers and upregulation of mesenchymal cell markers. P < 0.01 is based on Student’s t-test. Error bars, SD
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epithelial cell markers (E-cadherin and α-catenin)
were upregulated, whereas mesenchymal cell markers
(N-cadherin, fibronection, and vimentin) were down-
regulated, as determined by Western blot analysis
(Fig. 5a) and qRT-PCR (Fig. 5b) assay. Furthermore,
HOXD9 overexpression significantly increases the
mesenchymal cell markers and decreases the epithelial
cell markers (Fig. 5c and d). The same results were
obtained by immunofluorescence analysis (Additional
file 3: Figure S2a and b). The mRNA of the EMT
markers exhibited a trend consistent with the results
mentioned above. These results indicate that HOXD9
plays important roles in EMT.
HOXD9 can regulate ZEB1 expression
To elucidate the mechanisms in which HOXD9 is en-
gaged in the development and progression of liver can-
cer cells, microarray assay was performed by using cell
line MHCC97H-shHOXD9 #3 and its control cells with
an empty vector. Microarray results reveal that a list of
genes is significantly differentially expressed after
HOXD9 silencing (Fig. 6a). Gene set enrichment analysis
indicates that ZEB1 related gene signatures are signifi-
cantly enriched in HOXD9 knockdown cells (Fig. 6b).
This result supports the hypothesis that HOXD9 regu-
lates EMT and that cancer invasion and metastasis may
be mediated by ZEB1.
To further verify the relationship between HOXD9
and ZEB1, we evaluated the ZEB1 expression in liver
cancer cell lines constructed above by using Western
blot analysis and qRT-PCR. In cell lines with HOXD9
silencing, ZEB1 expression decreases significantly
compared with the control vector cells (Fig. 7a and
b). HOXD9 overexpression can increase the ZEB ex-
pression in protein and mRNA (Fig. 7c and d). We
analyze the ZEB1 mRNA expression in the same hu-
man HCC tissues to determine any clinical correlation
between HOXD9 and ZEB1. A highly positive correl-
ation between the HOXD9 and ZEB1 expression
levels is indicated similar to HOXD9 expression
(Fig. 7e). This result verifies the results of in vitro
and in vivo analyses.
We used a luciferase reporter controlled by the ZEB1
promoter to determine whether the binding of HOXD9 to
ZEB1 influences the transcriptional activity of the gene.
This reporter was inactivated in MHCC97H-shHOXD9
#3 cells but activated in Huh7-HOXD9 cells, thus reflect-
ing the endogenous activation of ZEB1 expression (Fig. 8a
and b). Quantitative chromatin immunoprecipitation
(qChIP) assays were performed in MHCC97H-shHOXD9,
Huh7-HOXD9, and their control cells to detect whether
HOXD9 regulates ZEB1 on a transcriptional level. Anti-
bodies against HOXD9 and IgG were used to pull down
the chromatin complex, and three pairs of primers (#1, #2,
and #3) against the ZEB1 gene promoter region were used
to assess the occupancy of the ZEB1 gene promoter
(Fig. 8c). Silencing HOXD9 expression was associated
with decreased levels at #1 and #3 of the ZEB1 gene
Fig. 6 HOXD9 regulates ZEB1 expression. a Clustering of genes differentially expressed after HOXD9 silencing. b Enrichment scores of differential
gene expression in the HOXD9-silencing cell line
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promoter region in MHCC97H-shHOXD9s cells (Fig. 8d
and e). A greater occupancy of the ZEB1 gene promoter
regions by HOXD9 was detected in Huh7-HOXD9 cells
(Fig. 8f and g). These results clearly indicate that HOXD9
induces the transcriptional activation of ZEB1 expression
by increasing HOXD9 to the ZEB1 gene promoter in
HCC cells.
ZEB1 mediates HOXD9-induced migration, invasion, and
EMT in HCC cells
To evaluate whether the HOXD9-induced metastatic
capacity was mediated by ZEB1, siRNAs were used to si-
lence the ZEB1 gene expression by virally transfecting
Huh7-HOXD9 cells with three distinct ZEB1 siRNAs.
Three cell lines with ZEB1 silencing were verified by
Fig. 7 ZEB1 expression is affected by HOXD9. a and b The ZEB1 expression levels in the HOXD9 silencing cell line were assayed by Western blot
analysis (a) and qRT-PCR (b). c and d Detecting ZEB1 expression in HOXD9 overexpression cell line by Western blot analysis (c) and qRT-PCR (d).
e ZEB1 expression was positively correlated with HOXD9 expression in liver cancer tissue arrays. P < 0.01 is based on the Student’s t- test. Error
bars, SD
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Western blot analysis and qRT-PCR (Fig. 9a and b).
The knockdown of ZEB1 decreased the migration and
invasion capacity of Huh7-HOXD9 cells (Fig. 9c). Epi-
thelial markers, E-cadherin, and α-catenin increase,
whereas mesenchymal markers, N-cadherin, vimentin,
and fibronectin decrease (Fig. 9d). These results indicate
the occurrence of EMT. Overall, these results show that
ZEB1 mediates HOXD9-induced EMT, migration, and in-
vasion in HCC cells.
Discussion
To our knowledge, this is the first study to show that
HOXD9 plays a functional role in liver cancer EMT and
distant metastasis. Silencing HOXD9 in liver cancer cells
Fig. 8 HOXD9 binding to the promoter of ZEB1 were assayed by ChIP-qPCR. a Effect of silencing HOXD9 expression on the activity of the ZEB1
promoter in MHCC97H and its control cells. b Effect of ectopic HOXD9 expression on the activity of the ZEB1 promoter in Huh7 and its control cells.
Data are presented as the ratio of firefly luciferase activity to sea pansy luciferase activity. pGL3 was used as a negative control for background. c
Schematic of the ZEB1 promoter region. d and f qChIP was performed in HOXD9 silencing (d) and overexpression (f) cell lines. e and g IgG was used
as a negative control. P < 0.01 is based on Student’s t-test. Error bars, SD
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inhibits EMT, migration, invasion, and EMT in vitro and
decreases the tumorigenic and metastatic capacities in
vivo. By contrast, HOXD9 overexpression reverses these
events in otherwise aggressive and invasive HCC breast
cells. Microarray data show that HOXD9 influences ZEN1
expression in HCC cells. Silencing ZEB1 in HOXD9 over-
expression cell lines obtains results that are similar to
those caused by HOXD9 knockdown.
Our results suggest that HOXD9 expression in HCC
cells was higher than that in normal cells. HOXD9 ex-
pression in glioma cancer stem cells has also been
shown to be higher than that in normal astrocytes and
NSPCs [8]. In this respect, HOXD9 may function as an
oncogene in cells. The expression disorder of genes be-
longing to the HOX family in cancer tissues has been re-
ported [23, 24]. A non-coding RNA residing in the
Fig. 9 Silencing ZEB1 in liver cancer cells decreases the migration and invasion of liver cancer cells. a Western blot analysis of ZEB1 levels in the
established HCC cell lines. b qRT-PCR analysis of ZEB1 levels in the established HCC cell lines. c Silencing ZEB1 reverses HOXD9-induced migration
and invasion in HCC cells d Silencing ZEB1 reverses the HOXD9-induced changes in EMT marker in HCC cells. P < 0.01 is based on the Student’s
t-test. Error bars, SD
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HOXC locus can act in translation to regulate the tran-
scription of the HOXD locus with polycomb-repressive
complex 2 [25]. The downregulation of non-coding
RNA expression and the changes in the methylation sta-
tus of the promoters may be related to the mechanism
of HOX gene misexpression in cancer cells [8]. HOXB9
has been found to regulate the tumor growth factor in
HCC and the metastatic behavior of HCC cells [26]. The
mechanism demonstrates the significance of the TGF-β1
pathway in HOXB9-induced EMT in HCC cells [27].
The effect on cell migration, invasion, and metastasis
also indicates that HOXD9 functions as an oncogene in
cancer cells. Silencing HOXD9 can significantly reduce
the migration and invasion of cancer cells in vitro. The
process also weakens the metastatic ability of cancers in
vivo. HOXD9 overexpression confers the opposite action
on the cell. Our study determines a novel function of
HOXD9 in HCC cell metastasis by regulating EMT.
EMT is an important cellular process in embryonic
development, tissue repair, and disease occurrence.
EMT was first introduced in the 1980s as a cellular
phenomenon in the primitive streak of chick embryos;
this process controls many developmental processes,
such as neural crest development and palate and lip
fusion [28]. EMT is a developmental programming
mechanism. EMT also significantly influences cancer
progression and confers certain fundamental abilities
to cancer cells that are essential for distant metastasis
[29, 30]. The precise contribution of EMT to cancer
metastasis remains unclear. One argument is that EMT
simply reflects genomic instability in cancer cells. Reports
have also suggested that EMT-driven cancer metasta-
sis can be induced by generating cancer stem cells
that are capable of colonizing other tissues to form
secondary tumors [11, 31].
The occurrence of EMT is accompanied by the altered
expression of molecular markers; thus, EMT can be de-
termined by detecting the expression of these molecular
markers [32]. Different expression levels of HODX9 lead
to different cell status. HOXD9 overexpression in HCC
cells promotes EMT. Our results also indicate that
HOXD9 promotes EMT, and silencing HOXD9 leads to
MET. This observation suggests that EMT-MET is a
fluid process. High HOXD9 expression also increases the
number of distant metastasis in vivo. This phenomenon is
consistent with the previous theory that EMT is essential
for tumor cells to disseminate from adjacent tissues and
seed new tumors in distant sites. These results indicate
that HOXD9 affect cell migration and invasion via EMT
regulation.
Microarray analysis was conducted to investigate
the mechanism of HOXD9 in regulating the development
of cancer. Zinc finger E-box-binding HOX 1, short for
ZEB1, was identified as an effective mediator of these
HOXD9-induced phenomena. Silencing ZEB1 in HOXD9
overexpression cell lines resulted in the similar
phenomenon caused by HOXD9 knockdown. ZEB1 has
been proven to induce EMT by acting repressing E-
cadherin, silencing E-cadherin by binding to the proximal
E-boxes [33, 34]. HOXD9 may be involved in the develop-
ment of HCC cells through the ZEB1 transcription factor.
Conclusions
In conclusion, HOXD9 upregulation can be correlated
with HCC development. The HOXD9-mediated induc-
tion of EMT is ZEB1 dependent, and HOXD9 inhibition
results in induction of a mesenchymal phenotype. These
findings suggest that HOXD9 activation can promote
ZEB1 in HCCs and elucidate HOXD9 signaling. These
results can also help identify potential targets in HCC
prevention and therapy.
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